Browse SULF2

Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Endoplasmic reticulum Golgi apparatus, Golgi stack Cell surface Note=Also localized on the cell surface.
Domain PF12548 Sulfatase protein
PF00884 Sulfatase
Function

Exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin.

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001655 urogenital system development
GO:0001819 positive regulation of cytokine production
GO:0001822 kidney development
GO:0001889 liver development
GO:0002062 chondrocyte differentiation
GO:0002063 chondrocyte development
GO:0003012 muscle system process
GO:0003014 renal system process
GO:0003094 glomerular filtration
GO:0006029 proteoglycan metabolic process
GO:0006606 protein import into nucleus
GO:0006790 sulfur compound metabolic process
GO:0006913 nucleocytoplasmic transport
GO:0006936 muscle contraction
GO:0006939 smooth muscle contraction
GO:0008543 fibroblast growth factor receptor signaling pathway
GO:0009100 glycoprotein metabolic process
GO:0010573 vascular endothelial growth factor production
GO:0010574 regulation of vascular endothelial growth factor production
GO:0010575 positive regulation of vascular endothelial growth factor production
GO:0014831 gastro-intestinal system smooth muscle contraction
GO:0014846 esophagus smooth muscle contraction
GO:0016055 Wnt signaling pathway
GO:0017038 protein import
GO:0021675 nerve development
GO:0022612 gland morphogenesis
GO:0030111 regulation of Wnt signaling pathway
GO:0030177 positive regulation of Wnt signaling pathway
GO:0030198 extracellular matrix organization
GO:0030201 heparan sulfate proteoglycan metabolic process
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0032386 regulation of intracellular transport
GO:0032388 positive regulation of intracellular transport
GO:0032835 glomerulus development
GO:0032836 glomerular basement membrane development
GO:0033157 regulation of intracellular protein transport
GO:0034504 protein localization to nucleus
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035413 positive regulation of catenin import into nucleus
GO:0035860 glial cell-derived neurotrophic factor receptor signaling pathway
GO:0040036 regulation of fibroblast growth factor receptor signaling pathway
GO:0040037 negative regulation of fibroblast growth factor receptor signaling pathway
GO:0042306 regulation of protein import into nucleus
GO:0042307 positive regulation of protein import into nucleus
GO:0043062 extracellular structure organization
GO:0044344 cellular response to fibroblast growth factor stimulus
GO:0044744 protein targeting to nucleus
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046824 positive regulation of nucleocytoplasmic transport
GO:0048706 embryonic skeletal system development
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051216 cartilage development
GO:0051222 positive regulation of protein transport
GO:0060070 canonical Wnt signaling pathway
GO:0060348 bone development
GO:0060384 innervation
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0061008 hepaticobiliary system development
GO:0061448 connective tissue development
GO:0071774 response to fibroblast growth factor
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072574 hepatocyte proliferation
GO:0072575 epithelial cell proliferation involved in liver morphogenesis
GO:0072576 liver morphogenesis
GO:0090263 positive regulation of canonical Wnt signaling pathway
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0090288 negative regulation of cellular response to growth factor stimulus
GO:0090316 positive regulation of intracellular protein transport
GO:0097205 renal filtration
GO:0097421 liver regeneration
GO:0198738 cell-cell signaling by wnt
GO:1900180 regulation of protein localization to nucleus
GO:1900182 positive regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903829 positive regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904591 positive regulation of protein import
GO:1904951 positive regulation of establishment of protein localization
GO:2000027 regulation of organ morphogenesis
GO:2000345 regulation of hepatocyte proliferation
Molecular Function GO:0004065 arylsulfatase activity
GO:0008449 N-acetylglucosamine-6-sulfatase activity
GO:0008484 sulfuric ester hydrolase activity
Cellular Component GO:0005795 Golgi stack
GO:0031984 organelle subcompartment
GO:0098791 Golgi subcompartment
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SULF2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SULF2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SULF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4030.434
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4010.838
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.9830.469
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3890.374
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.9150.695
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2750.926
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1450.788
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2470.886
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1070.953
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4330.819
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.0580.708
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.7530.00173
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SULF2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277318.55.5130.0572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275918.56.811.70.132
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.2022.20.12
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59400400.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SULF2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SULF2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SULF2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SULF2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SULF2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SULF2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSULF2
Namesulfatase 2
Aliases KIAA1247; HSULF-2; SULF-2; Extracellular sulfatase Sulf-2
Chromosomal Location20q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SULF2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.